Manufacturing, Fill/Finish

Bausch’s second generation Type 529 is a semi-automatic IV bag filling and closing machine designed for aseptic packaging of infusions, parenteral drugs, and other fluids with a fully integrated automatic closing system to eliminate possible contamination.

Genentech plans to invest more than $125 million in an expansion of its fill/finish facility in Hillsboro, OR.

McNeil-PPC pleads guilty in connection with adulterated infants' and children's over-the-counter liquid medications.

MedImmune will provide funds and access to monoclonal antibodies to seven postdoctoral associates for the creation of protein measurement and characterization tools.

Evaluating the assembly design process, manufacture, and use helps mitigate risk.

There are significant differences between small molecules and biologics fill/finish capacity.

Grand River Aseptic Manufacturing has announced that the company executed two commercial production contracts in one day.

IDT Biologika completes large-scale biologics finishing facility in Dessau, Germany.

PSC Investments announces the acquisition of a high potency, sterile fill/finish pharmaceutical manufacturing facility.

Merck KGaA fill-finish expansion in Italy will be completed in 2017.

Integrated Single-Use Sterile and SIP Connector Provide Flexibility

Aseptic Valve Range Increases Sterility

Displays will include new products for anticounterfeiting, labeling, and compliance packaging and new equipment for filling, aggregating, and quality control.

New injection-delivery systems with multiple closure points pose challenges for container closure integrity testing.

A novel approach to sterile drug product manufacturing uses a single-use assembly in a multi-product final filling suite with isolator technology.

FDA clarifies recommendations for injectable drug products packaged in vials and ampules.

Manufacturers are taking measures to comply with new package safety rules.

A novel approach to sterile drug product manufacturing that uses a single-use assembly in a multi-product final filling suite with isolator technology offers benefits of efficiency and flexibility.

A packaging defect has led to Merck voluntarily recalling all lots of Liptruzet tablets in the United States.

Wolfgang Weikmann of Vetter Pharma discusses the implementation of quality by design in sterile manufacturing.

ISPE’s survey is industry’s first large-scale effort to collect data on patient experiences with clinical trial materials.

BioPharm International speaks with industry experts about challenges faced in managing the cold chain.

USP is developing and revising distribution standards in response to changes in the global supply chain.

The authors discuss how to develop a cost-effective thermally protective packaging system.

Vetter is investing $100 million to expand filling capacity in Germany and the United States.

ATMI has invested in sterile-connector and sterile-fill technology developed by Medical Instill Technologies.

FDA Issues Draft Guidance on Patient Counseling Info for Labeling

As the Supreme Court ruled on generic-drug liability, FDA outlined new rules for warning labels.

Vetter has ready-to-submit documentation for this service in Common Technical Document (CTD) formats for the US, Europe and Japan.